FCER2 is an inclusion criterion in 3 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain FCER2 status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [4].

FCER2 is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FCER2 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

FCER2 is an inclusion criterion in 1 clinical trial for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, of which 1 is open and 0 are closed. Of the trial that contains FCER2 status and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue as inclusion criteria, 1 is phase 2 (1 open) [4].

FCER2 is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FCER2 status and follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FCER2 is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FCER2 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FCER2 is an inclusion criterion in 1 clinical trial for nodal marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FCER2 status and nodal marginal zone lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FCER2 is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains FCER2 status and Richter syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

FCER2 is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FCER2 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FCER2 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains FCER2 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].